Results 141 to 150 of about 143,744 (251)

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Clear cell renal cell carcinoma metastasizing to the thyroid gland: a case report. [PDF]

Front Oncol
Xia Z, Zhao Z, Sun P, Xu P, Li J.
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Molecular Evaluation of RNA-Based Immune Checkpoint Profiling in Clear Cell Renal Cell Carcinoma. [PDF]

J Clin Med
Giacobbi E, Palumbo V, Servadei F, Bonfiglio R, Moscato GMF, Carilli M, Vittori M, Iacovelli V, Bove P, Mauriello A, Scimeca M.   +10 more
europepmc   +1 more source

Mitochondria‐endoplasmic reticulum organelle glue as maturation promoter for origination/dimensional dual‐cross cardiomyocytes

BMEMat, EarlyView.
Mitochondria‐endoplasmic reticulum contact sites (MERCS) are areas where the mitochondria and endoplasmic reticulum closely interact. In this study, we utilize synthetic organelle glues to artificially engineer MERCS for regulating cardiomyocyte development, through which the immature and chemo‐plasticity issues of undifferentiated cells are addressed.
Wei Tang, Hao Sun, Chenqi Duan, Jiajia Chang, Yuxing Wang, Ming Zhao, Huiyue Zhao, Shan Lu, Yang Yang, Da Huo   +9 more
wiley   +1 more source

ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma. [PDF]

Cancer Res
Koh J, Liao C, Ng MSW, Hong JH, Heng HL, Gui DY, Wang Z, Chua BY, Li Z, Sobota RM, Lee LS, Iqbal J, Lim KJ, Bezwada D, DeBerardinis RJ, Steger G, Ching J, Tan P, Teh BT, Zhang Q, Yao X.   +20 more
europepmc   +1 more source

Carbon Dots for Cancer Theranostics: Synthesis Strategies, Luminescence Properties, and Advances in Bioimaging‐Guided Diagnosis and Therapy

Chemistry – A European Journal, EarlyView.
Lighting up the path to precision oncology: This review comprehensively summarizes the rational design of carbon dots (CDs), elucidating how core size, surface chemistry, and heteroatom doping dictate their luminescence mechanisms. Special emphasis is placed on engineering NIR‐II emissive CDs for deep‐tissue imaging.
Zekun Yan, Yupeng Liu, Jinyun Tan, Songnan Qu   +3 more
wiley   +1 more source

Deep Learning Identification of Clear Cell Renal Cell Carcinoma on MR Imaging. [PDF]

J Comput Assist Tomogr
Guo J, Haddad G, Xi Y, Hinojosa L, Hulsey K, Albayrak E, Pedrosa I.   +6 more
europepmc   +1 more source

From Metabolic Crisis to Molecular Classification: Multidisciplinary Management of Synchronous Endometrioid Ovarian and Endometrial Carcinomas With Massive Tumor Burden

Cancer Nexus, EarlyView.
Managing massive tumor burden in synchronous endometrioid carcinomas. The graphical abstract summarizes the clinical pathway from presentation with massive ascites, pleural effusion, and critical metabolic abnormalities to multidisciplinary stabilization, surgical management, integrated morphologic–molecular classification, and shared decision‐making ...
Anna Homeniuk, Leena Abdalla, Sharon Fitzgerald   +2 more
wiley   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source